Dogwood Therapeutics 将来の成長

Future 基準チェック /06

Dogwood Therapeuticsの収益は年間21.6%で減少すると予測されていますが、年間収益は年間79.6%で増加すると予想されています。EPS は年間24.4%で増加すると予想されています。

主要情報

-21.6%

収益成長率

24.4%

EPS成長率

Biotechs 収益成長	28.4%
収益成長率	79.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	11 Nov 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jun 25

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Mar 09

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Nov 02

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Jul 19

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Jun 04

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Mar 31

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Feb 01

Virios Therapeutics prices IPO at $10

Dec 17

業績と収益の成長予測

NasdaqCM:DWTX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-14	-16	N/A	3
12/31/2025	N/A	-10	-9	N/A	3
12/31/2024	N/A	-6	-6	N/A	3
9/30/2024	N/A	-6	-4	-4	N/A
6/30/2024	N/A	-5	-4	-4	N/A
3/31/2024	N/A	-5	-4	-4	N/A
12/31/2023	N/A	-5	-5	-5	N/A
9/30/2023	N/A	-6	-6	-6	N/A
6/30/2023	N/A	-8	-8	-8	N/A
3/31/2023	N/A	-10	-11	-11	N/A
12/31/2022	N/A	-12	-11	-11	N/A
9/30/2022	N/A	-15	-14	-14	N/A
6/30/2022	N/A	-16	-14	-14	N/A
3/31/2022	N/A	-17	-13	-13	N/A
12/31/2021	N/A	-16	-16	-16	N/A
9/30/2021	N/A	-18	-13	-13	N/A
6/30/2021	N/A	-17	-11	-11	N/A
3/31/2021	N/A	-13	-9	-9	N/A
12/31/2020	N/A	-10	-4	-4	N/A
9/30/2020	N/A	-4	-2	-2	N/A
6/30/2020	N/A	-3	-2	-2	N/A
3/31/2020	N/A	-2	-2	-2	N/A
12/31/2019	N/A	-2	-2	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DWTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DWTX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: DWTX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: DWTX来年は収益がないと予測されています。

高い収益成長: DWTX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DWTXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Dogwood Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target increased by 92% to US$83.33

Price target decreased to US$2.00

Recent updates

Dogwood Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Listing Rule 5550(b)(1)

Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study

New major risk - Revenue and earnings growth

Dogwood Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Price target increased by 92% to US$83.33

Virios Therapeutics, Inc. Appoints Angela Walsh as Chief Financial Officer

Virios Therapeutics, Inc. (NasdaqCM:VIRI) acquired Pharmagesic (Holdings) Inc. from Sealbond Limited.

New major risk - Financial position

Virios Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Virios Therapeutics, Inc. Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

New major risk - Revenue and earnings growth

Nasdaq Grants Exception Till October 28 to Virios Therapeutics to Regain Compliance with Minimum Bid Price Requirement

Virios Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $1.7 million.

New major risk - Shareholder dilution

Virios Therapeutics, Inc. has filed a Follow-on Equity Offering.

Virios Therapeutics, Inc. Receives Another Letter from Nasdaq

Virios Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Virios Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

New major risk - Revenue and earnings growth

Virios Therapeutics Announces Plans to Advance Development of Imc-2 as Treatment for Symptoms Associated with Long-Covid

New major risk - Market cap size

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Insufficient new directors

New major risk - Financial position

Virios Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Virios Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New major risk - Market cap size

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Virios Therapeutics, Inc. Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as A New Treatment Option for Fibromyalgia

Virios Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-Covid Symptoms Following Treatment with A Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Can Virios Therapeutics (NASDAQ:VIRI) Afford To Invest In Growth?

Virios Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023

Price target decreased to US$2.00

High number of new directors

Virios Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Virios Therapeutics Receives Letter Regarding Bid Price Requirement from the Listing Qualifications Department of the Nasdaq

Virios Therapeutics, Inc. Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Virios Therapeutics slides 11% postmarket on proposed stock offering

Virios Therapeutics, Inc. Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Virios Therapeutics GAAP EPS of -$0.44 beats by $0.07

Virios Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell Microcap Value Index

Here's Why We're Watching Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Founder & Director recently bought US$59k worth of stock

Virios Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new directors

Is Virios Therapeutics (NASDAQ:VIRI) In A Good Position To Invest In Growth?

Virios Therapeutics Inc. Withdraws its Application for Investigational New Drug (IND 157311)

Virios Therapeutics, Inc. Achieves over 50% Enrollment Milestone in Its Phase 2B Clinical Trial for Fibromyalgia

Will Virios Therapeutics (NASDAQ:VIRI) Spend Its Cash Wisely?

Virios Therapeutics Receives New Patent for Antiviral Inhibitor Combination

Here's Why We're Not Too Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Situation

Virios Therapeutics, Inc.(NasdaqCM:VIRI) dropped from Russell Microcap Growth Index

Virios Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating IMC-1 in Patients with Fibromyalgia

Virios Therapeutics shares rise after dosing first patient in mid-stage fibromyalgia study

Virios Therapeutics (NASDAQ:VIRI) Is In A Good Position To Deliver On Growth Plans

Virios Therapeutics, LLC to Report Q4, 2020 Results on Mar 18, 2021

Virios Therapeutics, Inc. Announces Research Collaboration to Explore Role of HSV-1 in Irritable Bowel Syndrome

Virios Therapeutics gains 10% on research deal in irritable bowel syndrome

Virios Therapeutics, LLC has completed an IPO in the amount of $30 million.

Virios Therapeutics prices IPO at $10

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘